Physician profile
Grace Levy-Clarke
NPI 1437342847
$18,533.98
in general payments reported to CMS, 2019-2025
14 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $127 · 2021: $78.82 · 2022: $390 · 2023: $200 · 2024: $1,575 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,575 · Travel and Lodging: $471 · Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,575.00 |
| Travel and Lodging | $470.60 |
| Food and Beverage | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,044.93 | 2019-2023 | |
| Abbvie INC. | $7,457.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $1,575.00 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $522.01 | 2020-2025 | Acthar |
| Allergan, INC. | $355.19 | 2019 | |
| Horizon Therapeutics Plc | $185.22 | 2020-2023 | Uplizna |
| Kala Pharmaceuticals, INC. | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $84.23 | 2022 | |
| Mallinckrodt Enterprises LLC | $71.60 | 2019 | |
| Gilead Sciences, INC. | $39.98 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.99 | 2019 | |
| Genentech, INC. | $20.46 | 2023 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $14.02 | 2019 | |
| Alcon Vision LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Levy-Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.